CompletedNot Applicable

HIV Persistence in Lymph Node and Peripheral Blood

Australia8 participantsStarted 2017-01-02

Plain-language summary

The aim of this project is to determine whether latent HIV is enriched in cells expressing certain proteins (receptors) on their surface and whether it is possible to eliminate these cells through the use of drugs that specifically target these proteins. Lymph nodes are known to contain very high numbers of HIV infected cells.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Written Informed Consent * Willing to undergo leukapheresis and lymph node biopsy * Documented HIV-1 infection (antibody positive or detectable plasma HIV-1 RNA) * Receiving combination ART * HIV RNA \< 50 copies/mL for \> 3 years (Episodes of a single HIV plasma RNA 50-500 copies/mL will not exclude participation if the subsequent HIV plasma RNA was \<50 copies/mL) Exclusion Criteria: * Unwillingness to follow protocol requirements * Contraindications to LN biopsy or leukapheresis * Current skin infection of inguinal area * Known current lower extremity, gastrointestinal or genitourinary infection

What they're measuring

Frequency of HIV-1 in cells expressing CTLA4 and PD-1 in lymph node derived cells

Timeframe: Baseline only

Trial details

NCT IDNCT03426189

SponsorUniversity of Melbourne

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2018-10-17

View on ClinicalTrials.gov More HIV-1-infection trials